TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
Equity
Tango Therapeutics, Inc. (TNGX) Stock — Today's Move
$22.20
$-1.15 today
TNGX is down 4.91% today. Volume is 5.37M vs a 30-day average of 4.14M (1.30x).
Day High
$23.95
Day Low
$22.00
Open
$23.41
Prev Close
$23.34
Volume
5.37M
Avg Vol (30d)
4.14M
52-Wk High
$34.39
52-Wk Low
$7.12
Sector
—
Today's Move
-4.91%
Next Earnings
Tue, Nov 10
Tango Therapeutics, Inc. is scheduled to report earnings Tue, Nov 10, 2026. Analysts expect EPS of $-0.36. Stocks often move sharply on earnings day.
52-wk low $7.1252-wk high $34.39
TNGX is 55% of the way from its 52-week low to its high.
Indicators:
Close price · volume bars (dashed line = average volume) · news that day (2M–1Y) — hover or tap the chart. Indicators are for education, not trading advice.
Why is TNGX moving today?
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
Tango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line…
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic an…
Tango Therapeutics stock falls despite positive cancer trial data
Investing.com -- Tango Therapeutics (NASDAQ:TNGX) shares fell 6% Friday following the company’s presentation of Phase 1/2 study results for vopimetostat and daraxonrasib in pancre…
Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patien…
Related Movers
XP
▼ -48.36%
XP Inc.
Gap Stock Movers: SGRY Leads Gap-Ups and XP Leads Gap-Downs in Today's Session
$15.71
-$14.71
INTR
▼ -34.91%
Inter & Co. Inc.
S&P Index Addition Could Change The Case For Inter (INTR) Stock
$4.68
-$2.51
BBD
▼ -28.01%
Banco Bradesco Sa
Most Active Stocks on Oct. 26: RCT, NU and BBD Top Volume
$2.93
-$1.14
SBS
▼ -26.09%
Companhia de saneamento Basico
$4.73
-$1.67
FAQ — TNGX
Why is TNGX moving today?
TNGX is down 4.91% in the current session. Scroll to the news section below to see the most recent headlines and catalysts driving the move.
Is Tango Therapeutics, Inc. a good stock to buy today?
WeeklyTrader.io does not provide financial advice. Always verify catalysts, assess risk, and conduct your own research before making any investment decision.
What is TNGX's average volume?
Average volume for TNGX is approximately 4.14M shares per day based on the trailing 30 sessions.